[go: up one dir, main page]

AR086709A1 - Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos - Google Patents

Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos

Info

Publication number
AR086709A1
AR086709A1 ARP120102226A ARP120102226A AR086709A1 AR 086709 A1 AR086709 A1 AR 086709A1 AR P120102226 A ARP120102226 A AR P120102226A AR P120102226 A ARP120102226 A AR P120102226A AR 086709 A1 AR086709 A1 AR 086709A1
Authority
AR
Argentina
Prior art keywords
formula
pharmaceutically acceptable
halogen
methyl group
compound
Prior art date
Application number
ARP120102226A
Other languages
English (en)
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46513798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086709(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Publication of AR086709A1 publication Critical patent/AR086709A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos de fórmula (1) y los derivados farmacéuticamente aceptables de aquellos, donde R1, R4, R8, R9, y m son como se han definido en la presente, las composiciones que comprenden una cantidad efectiva de un compuesto de fórmula (1) o un derivado farmacéuticamente aceptable de aquellos, y los métodos para tratar o prevenir una condición tal como dolor, dolor asociado con osteoartritis, osteoartritis, IU, una úlcera, IBD, e lBS, que comprende administrar a un animal que lo necesita una cantidad efectiva de un compuesto de fórmula (1) o un derivado farmacéuticamente aceptable de aquel.Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o un derivado farmacéuticamente aceptable de aquel, donde: R1 es -halógeno o -CF3; R4 es -H o -CH3; cada uno de R8 y R9 es independientemente -H, -halógeno, -CH3, -CF3, -OCH3, -OCF3, -OCH2CH3, -CH2OCH3, o -C(O)OR10; R10 es -alquilo C1-4; cada halógeno es independientemente -F, -Cl, -Br, o I; y m es el número entero 0 ó 1; (i) con la condición que si R4 es -H entonces m es 1; y (ii) con la condición que si R4 es -H y el átomo de carbono en la posición a del enlace a-b está en la configuración (S), entonces el grupo metilo unido al anillo de piperazina es un grupo (S)-2-metilo, un grupo (S)-3-metilo, o un grupo (R)-3-metilo.
ARP120102226A 2011-06-22 2012-06-21 Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos AR086709A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161499989P 2011-06-22 2011-06-22

Publications (1)

Publication Number Publication Date
AR086709A1 true AR086709A1 (es) 2014-01-15

Family

ID=46513798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102226A AR086709A1 (es) 2011-06-22 2012-06-21 Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos

Country Status (34)

Country Link
US (4) US9273043B2 (es)
EP (2) EP2723732B1 (es)
JP (1) JP5699251B2 (es)
KR (2) KR20150055094A (es)
CN (2) CN105693712A (es)
AR (1) AR086709A1 (es)
AU (1) AU2012273652B2 (es)
BR (1) BR112013032658A2 (es)
CA (1) CA2837178C (es)
CL (1) CL2013003550A1 (es)
CO (1) CO6852081A2 (es)
CY (1) CY1119111T1 (es)
DK (1) DK2723732T3 (es)
ES (1) ES2620528T3 (es)
HR (1) HRP20170507T1 (es)
HU (1) HUE031372T2 (es)
IL (1) IL229817A (es)
LT (1) LT2723732T (es)
ME (1) ME02609B (es)
MX (1) MX354015B (es)
MY (1) MY185061A (es)
PE (1) PE20141531A1 (es)
PH (1) PH12013502412B1 (es)
PL (1) PL2723732T3 (es)
PT (1) PT2723732T (es)
RS (1) RS55701B1 (es)
RU (1) RU2621708C2 (es)
SG (2) SG10201605163PA (es)
SI (1) SI2723732T1 (es)
SM (1) SMT201700197T1 (es)
TW (1) TWI453205B (es)
UA (1) UA113288C2 (es)
WO (1) WO2012176061A1 (es)
ZA (1) ZA201400419B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2723732T (lt) * 2011-06-22 2017-02-27 Purdue Pharma Lp Trpv1 antagonistai, įskaitant dihidroksi pakaitą, ir jų panaudojimas
KR101933622B1 (ko) * 2012-10-09 2018-12-28 삼성전자주식회사 소포를 모니터링하기 위한 조성물, 키트 및 이를 이용하여 소포를 모니터링하는 방법
CN107710607B (zh) * 2015-07-31 2021-04-20 株式会社村田制作所 天线匹配电路、天线电路、前端电路以及通信装置
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN113077942B (zh) * 2021-04-12 2021-12-17 西北工业大学 一种基于功率超声制备智能柔性导电薄膜及其应用
WO2024095962A1 (ja) 2022-10-31 2024-05-10 塩野義製薬株式会社 Ｔｒｐｖ１アンタゴニストであるピリジン誘導体の使用

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4409229A (en) 1977-12-02 1983-10-11 Hoechst-Roussel Pharmaceuticals, Inc. Antidepressive and tranquilizing substituted 1,3-dihydrospiro[benzo(c)thiophene]s
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH0680054B2 (ja) 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
JPS6289679U (es) 1985-11-22 1987-06-08
US4797419A (en) 1986-11-03 1989-01-10 Warner-Lambert Company Method of treating the symptoms of senile cognitive decline employing di- or trisubstituted urea cholinergic agents
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
DE3905364A1 (de) 1989-02-22 1990-08-23 Hoechst Ag Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
UA37178C2 (uk) 1990-06-07 2001-05-15 Астразенека Аб Терапевтичні гетероциклічні сполуки, спосіб їх одержання, спосіб профілактики та лікування, лікарський засіб та спосіб його одержання
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3191429B2 (ja) 1992-09-02 2001-07-23 富士通テン株式会社 電子機器の挿排装置
NZ254550A (en) 1992-09-28 1997-08-22 Pfizer Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
JP2606138Y2 (ja) 1993-04-20 2000-09-25 株式会社小松製作所 クラッチ作動圧力検出手段を備えたクラッチ油圧制御弁装置
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
JPH11507670A (ja) 1995-06-12 1999-07-06 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ−２インヒビターと５−リポキシゲナーゼインヒビターの組合せによる炎症と炎症関連疾患の治療
CZ292327B6 (cs) 1995-09-07 2003-09-17 F. Hoffmann-La Roche Ag Derivát 4-(oxyalkoxyfenyl)-3-oxypiperidinu, způsob jeho přípravy, meziprodukt pro jeho přípravu a farmaceutický prostředek, který ho obsahuje
EP0861075A1 (en) 1995-11-13 1998-09-02 Albany Medical College Analgesic compounds and uses thereof
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5854245A (en) 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US5990107A (en) 1996-06-28 1999-11-23 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US5798360A (en) 1996-08-01 1998-08-25 Isis Pharmaceuticals, Inc. N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
ATE253111T1 (de) 1997-08-20 2003-11-15 Univ California Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
JPH11199573A (ja) 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd ５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
AU745425B2 (en) 1998-01-27 2002-03-21 Aventis Pharmaceuticals Inc. Substituted oxoazaheterocyclyl factor Xa inhibitors
EP0943683A1 (en) 1998-03-10 1999-09-22 Smithkline Beecham Plc Human vanilloid receptor homologue Vanilrep1
EP1087962A4 (en) 1998-06-19 2001-10-04 Lilly Co Eli PRODUCTION OF HETEROARYL COMPOUNDS
WO2000001688A1 (en) 1998-07-02 2000-01-13 Sankyo Company, Limited Five-membered heteroaryl compounds
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
JP2002535256A (ja) 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 化合物および方法
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
KR20020005653A (ko) 1999-04-01 2002-01-17 실버스타인 아써 에이. 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘
AU4797400A (en) 1999-05-17 2000-12-05 Eli Lilly And Company Metabotropic glutamate receptor antagonists
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
AU7514700A (en) 1999-09-07 2001-04-10 Syngenta Participations Ag Cyanopiperidines
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
KR100526487B1 (ko) 2000-06-21 2005-11-08 에프. 호프만-라 로슈 아게 벤조티아졸 유도체
AR028782A1 (es) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd Derivados heterociclicos tetrahidropiridino o piperidino
DE60132456T2 (de) 2000-07-13 2009-01-08 Merck Patent Gmbh Chirale verbindungen i
JP2004525071A (ja) 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
IL154927A0 (en) 2000-10-18 2003-10-31 Pfizer Prod Inc Combination of statins and sorbitol dehydrogenase inhibitors
HRP20030420A2 (en) 2000-11-30 2004-08-31 Pfizer Prod Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors
US7193113B2 (en) 2000-12-15 2007-03-20 Japan Science And Technology Corporation Arylbis(perfluoroalkylsulfonyl) methane and metallic salt thereof, and methods for producing the same
US20030232996A1 (en) 2001-04-20 2003-12-18 Brown David L Regioselective synthesis of 3,4-di{(carboclyl or heterocyclyl)thiophenes
AU2002305450A1 (en) 2001-05-08 2002-11-18 Yale University Proteomimetic compounds and methods
US20040038982A1 (en) 2001-07-13 2004-02-26 Bondinell William E. Compounds and methods
JP2003095951A (ja) 2001-09-25 2003-04-03 Sumitomo Pharmaceut Co Ltd 慢性関節リウマチ治療剤
US20040259912A1 (en) 2001-09-28 2004-12-23 Takahiro Matsumoto Benzine derivatives, process for preparing the same and use thereof
AU2002360621B2 (en) 2001-12-19 2007-01-25 Merck & Co., Inc. heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
US20050119251A1 (en) 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
JP2003192673A (ja) 2001-12-27 2003-07-09 Bayer Ag ピペラジンカルボキシアミド誘導体
WO2003066595A2 (en) 2002-02-01 2003-08-14 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
ATE416168T1 (de) 2002-02-15 2008-12-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
AU2003218736B2 (en) 2002-03-13 2009-01-08 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
CN1150176C (zh) 2002-05-22 2004-05-19 上海医药工业研究院 芳烷酮哌嗪衍生物及其应用
WO2003099266A2 (en) 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
EP1522314B1 (en) 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
EA200500114A1 (ru) 2002-06-28 2005-06-30 Еуро-Селтик, С. А. Терапевтические агенты, используемые для лечения боли
EP1388538B1 (en) 2002-07-09 2010-09-01 Merck Patent GmbH Polymerisation Initiator
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004010942A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP1550662B1 (en) 2002-09-27 2012-07-04 Dainippon Sumitomo Pharma Co., Ltd. Adenine compound and use thereof
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP1596869B1 (en) 2003-01-21 2014-06-04 New Form Pharmaceuticals Inc. Novel cocrystallization
US7223788B2 (en) 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
EP1627869B1 (en) 2003-05-20 2012-05-02 Ajinomoto Co., Inc. Vanilloid receptor modulators
TWI287010B (en) 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
US20050009841A1 (en) 2003-07-11 2005-01-13 Zheng Guo Zhu Novel amides useful for treating pain
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
CN1856484B (zh) 2003-07-24 2010-09-22 欧洲凯尔蒂克公司 用于治疗或预防疼痛的杂芳基-四氢吡啶基化合物
CA2533509C (en) 2003-07-24 2011-02-22 Euro-Celtique S.A. Piperidine compounds and pharmaceutical compositions containing them
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
BRPI0413059A (pt) 2003-07-29 2006-10-31 Xenon Pharmaceuticals Inc derivados de piridila e seu uso como agentes terapêuticos
JP4782008B2 (ja) 2003-07-30 2011-09-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリジル誘導体および治療剤としてのその用途
CA2533901A1 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1648874B1 (en) 2003-07-30 2011-10-05 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
CN101712653A (zh) 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2005012287A1 (en) 2003-08-01 2005-02-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005016910A1 (ja) 2003-08-18 2005-02-24 Sankio Chemical Co., Ltd. ピリジルテトラヒドロピリジン類およびピリジルピペリジン類とそれらの製造方法
ATE496048T1 (de) 2003-09-22 2011-02-15 Euro Celtique Sa Phenylcarboxamidverbindungen zur schmerzbehandlung
AU2004276252B2 (en) 2003-09-22 2007-11-22 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2005037284A1 (en) 2003-10-15 2005-04-28 Pfizer Products Inc. Sorbitol dehydrogenase inhibitor and hypertensive agent combinations
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1727801B1 (en) 2003-12-30 2009-02-18 Euro-Celtique S.A. Piperazines useful for treating pain
US7355045B2 (en) 2004-01-05 2008-04-08 Applera Corporation Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
AR051095A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006051047A1 (en) * 2004-11-09 2006-05-18 Ciba Specialty Chemicals Holding Inc. N-substituted imides as polymerization initiators
US20060116368A1 (en) 2004-11-29 2006-06-01 Calvo Raul R 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
US20060223849A1 (en) 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
DE102005014904A1 (de) 2005-03-26 2007-02-01 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
CA2621164A1 (en) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Derivative having ppar agonistic activity
BRPI0616574A2 (pt) 2005-09-27 2009-11-24 Shionogi & Co derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
US20070155707A1 (en) 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
AU2007207149A1 (en) 2006-01-18 2007-07-26 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US20080182851A1 (en) 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
DE102006060598A1 (de) 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
US7998966B2 (en) 2007-04-13 2011-08-16 Supergen, Inc. Axl kinase inhibitors
NZ580266A (en) 2007-04-27 2012-03-30 Purdue Pharma Lp Trpv1 inhibitors / antagonists and uses thereof
AU2008246202B2 (en) 2007-04-27 2011-12-01 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8158677B2 (en) 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
WO2008156610A2 (en) 2007-06-13 2008-12-24 Northeastern University Antibiotic compounds
US20100249144A1 (en) 2007-06-28 2010-09-30 Demong Duane Eugene Substituted piperazines as cb1 antagonists
JP2010532382A (ja) 2007-06-29 2010-10-07 エモリー・ユニバーシテイ 神経保護のためのｎｍｄａ受容体拮抗薬
CN101796048A (zh) 2007-07-09 2010-08-04 阿斯利康(瑞典)有限公司 用于治疗增殖病症的三取代的嘧啶衍生物
MX2010001486A (es) 2007-08-09 2010-03-01 Abbott Lab Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
ES2428326T3 (es) 2007-10-04 2013-11-07 Merck Sharp & Dohme Corp. Derivados de aril sulfona sustituida como bloqueadores de canales de calcio
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
US7935817B2 (en) 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
JP2009249346A (ja) 2008-04-08 2009-10-29 Fujifilm Corp ピリジン骨格を有する血液脳関門透過性化合物
US20110104301A1 (en) 2008-05-30 2011-05-05 Georgetown University, A Congressionally Chartered Institution Of Higher Education Methods of reducing pain and inflammation
MY153948A (en) 2008-07-21 2015-04-15 Purdue Pharma Lp Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
EP2414348B1 (en) 2009-04-03 2013-11-20 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders
CN103025723A (zh) 2010-05-27 2013-04-03 拜尔农作物科学股份公司 作为杀真菌剂的吡啶基羧酸衍生物
JP5876423B2 (ja) 2010-06-22 2016-03-02 塩野義製薬株式会社 Ｔｒｐｖ１阻害活性を有する化合物とその使用
WO2012047764A1 (en) 2010-10-04 2012-04-12 Intermune, Inc. Therapeutic antiviral peptides
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
CN103189371B (zh) 2010-11-04 2015-04-01 施万生物制药研发Ip有限责任公司 丙型肝炎病毒抑制剂
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
US20120202794A1 (en) 2011-01-24 2012-08-09 Pharmasset, Inc. Compounds
WO2012117421A1 (en) 2011-03-02 2012-09-07 Orchid Research Laboratories Ltd Histone deacetylase inhibitors
CN102336720B (zh) 2011-03-02 2016-01-13 华中科技大学 2-氨基噻唑衍生物及制备方法和应用
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
LT2723732T (lt) 2011-06-22 2017-02-27 Purdue Pharma Lp Trpv1 antagonistai, įskaitant dihidroksi pakaitą, ir jų panaudojimas
WO2013019621A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013066831A1 (en) 2011-10-31 2013-05-10 Glaxosmithkline Llc Compounds and methods
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
AU2013202973C9 (en) 2012-01-25 2016-12-22 Novartis Ag Heterocyclic compounds and methods for their use
WO2013142628A2 (en) 2012-03-20 2013-09-26 Fred Hutchinson Cancer Research Center Antibiotic compounds and compositions, and methods for identification thereof
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CA2873075A1 (en) 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
JP5699251B2 (ja) 2015-04-08
UA113288C2 (xx) 2017-01-10
JP2014520139A (ja) 2014-08-21
CY1119111T1 (el) 2018-02-14
WO2012176061A9 (en) 2013-03-14
RU2014101255A (ru) 2015-07-27
US10450308B2 (en) 2019-10-22
US9630959B2 (en) 2017-04-25
HUE031372T2 (en) 2017-07-28
SG10201605163PA (en) 2016-08-30
KR101589837B1 (ko) 2016-01-29
HRP20170507T1 (hr) 2017-06-02
US20160222002A1 (en) 2016-08-04
MX354015B (es) 2018-02-08
ME02609B (me) 2017-06-20
NZ618912A (en) 2015-07-31
CA2837178C (en) 2016-09-20
CO6852081A2 (es) 2014-01-30
SG195136A1 (en) 2013-12-30
ZA201400419B (en) 2015-04-29
PH12013502412B1 (en) 2022-03-23
AU2012273652B2 (en) 2015-09-03
CL2013003550A1 (es) 2014-11-14
EP3173411B1 (en) 2018-05-09
EP2723732B1 (en) 2017-01-18
TWI453205B (zh) 2014-09-21
MX2014000344A (es) 2015-09-23
WO2012176061A1 (en) 2012-12-27
KR20150055094A (ko) 2015-05-20
DK2723732T3 (en) 2017-04-03
US9273043B2 (en) 2016-03-01
SI2723732T1 (sl) 2017-05-31
PL2723732T3 (pl) 2017-07-31
CN103717594B (zh) 2016-12-14
WO2012176061A8 (en) 2013-08-08
CN105693712A (zh) 2016-06-22
LT2723732T (lt) 2017-02-27
SMT201700197T1 (it) 2017-05-08
BR112013032658A2 (pt) 2017-11-07
KR20140022469A (ko) 2014-02-24
US20140329829A1 (en) 2014-11-06
EP3173411A1 (en) 2017-05-31
AU2012273652A1 (en) 2013-05-02
ES2620528T3 (es) 2017-06-28
PE20141531A1 (es) 2014-10-23
PH12013502412A1 (en) 2014-01-06
CA2837178A1 (en) 2012-12-27
CN103717594A (zh) 2014-04-09
IL229817A (en) 2016-04-21
US20170183337A1 (en) 2017-06-29
RU2621708C2 (ru) 2017-06-07
EP2723732A1 (en) 2014-04-30
PT2723732T (pt) 2017-02-17
RS55701B1 (sr) 2017-07-31
TW201313707A (zh) 2013-04-01
MY185061A (en) 2021-04-30
US20200239460A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
AR092538A1 (es) Inhibidores de girasa triciclica
ES2626555T3 (es) Pyridone amides como moduladores de canales de sodio
AR086709A1 (es) Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos
AR094668A1 (es) Amidas como moduladores de canales de sodio
AR100442A1 (es) Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal
CY1119015T1 (el) 4'-αζιδο-3'φθορο υποκατεστημενα νουκλεοζιδιου παραγωγα ως αναστολεις αντιγραφης hcv rna
AR087418A1 (es) Inhibidores de replica de virus de influenza
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR085004A1 (es) Inhibidores selectivos de glicosidasas y usos de los mismos
CL2017002610A1 (es) Compuestos derivados de triazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015)
AR078151A1 (es) Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas.
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
CO6351793A2 (es) \"derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR094550A1 (es) Inhibidores de btk
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CO6531418A2 (es) Estabilizante de amina estéricamente inhibida
DOP2015000002A (es) Derivados de azaindol que actuan como inhibidores de p13k

Legal Events

Date Code Title Description
FB Suspension of granting procedure